Subscribe: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies
http://img.marketwire.com/rss/mwPBES.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
announces  company  development  jun  june  marketwired jun  marketwired june  marketwired  new  otc pink  pain  pleased announce 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies

Marketwired - Equipment and Supplies



Marketwired - Equipment and Supplies



Last Build Date: Mon, 26 Jun 2017 09:38:36 EDT

Copyright: Copyright: (C) Marketwired
 



Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R)

Mon, 26 Jun 2017 08:30:00 EDT

Company to narrow its business focus to pain and hypertension; Company plans to sell or divest the oligonucleotide therapeutic assets




Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

Mon, 26 Jun 2017 08:30:00 EDT

Pathway Set for PRP to Progress to First-In-Human Studies




Atossa Genetics Receives Positive Safety Committee Assessment of First Cohort Receiving Oral Formulation of Endoxifen in Phase 1 Dose Escalation Study

Mon, 26 Jun 2017 08:00:00 EDT

SEATTLE, WA--(Marketwired - Jun 26, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received a positive interim safety assessment of the first cohort receiving proprietary oral Endoxifen in its Phase 1 dose escalation study. Endoxifen is an active metabolite of the FDA approved drug tamoxifen, which is indicated for breast cancer and breast cancer prevention in high-risk patients. The Independent Safety Committee reviewed the blinded data generated from the first cohort receiving the oral formulation (8 subjects) and concluded that the study may advance to the next oral dosing level.




Moleculin Announces Scientific Support for Research Endeavor at Mayo Clinic

Mon, 26 Jun 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - June 26, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has entered into an agreement with a physician at the Mayo Clinic to enable additional research on Moleculin's WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor.




Vascular and Neural Complications in Rodent Models of Obesity and Type 2 Diabetes, New Webinar Hosted by Xtalks

Mon, 26 Jun 2017 07:30:00 EDT

In a live session on Wednesday, July 12, 2017 featured speaker Dr. Mark Yorek, Professor of Medicine at University of Iowa and Associate Chief of Staff for Research at Iowa City VA, will present vascular and neural complications in rodent models of obesity and type 2 diabetes. Specifically, he will present the characterization of peripheral neuropathy in translational animal models such as the ZDSD rat




Two Ogilvy CommonHealth Worldwide Executives Appointed to Judge the 2017 MM&M Awards

Mon, 26 Jun 2017 07:00:00 EDT

PARSIPPANY, NJ--(Marketwired - Jun 26, 2017) -  Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced two of the network's executives, Scott Watson and Johanna Skilling, from the New Jersey office have been selected as jurors for the 2017 MM&M Awards.




Cosmos Holdings Signs Letter of Intent To Acquire CC Pharma GmbH A Leading Re-importer of EU Pharmaceuticals to Germany

Fri, 23 Jun 2017 15:44:30 EDT

CC Pharma GmbH had revenues of approximately $200M in 2016




Jacobson Pharma Announces 2017 Annual Results

Fri, 23 Jun 2017 12:33:38 EDT

Revenue Increases 15.9% to HK$1,256.0 Million; Adjusted Net Profit Up by 30.7% to HK$201.9 Million; Recommends a Final Dividend of HK1.4 Cents per Share




Cannabis Science Invests in the Research and Development of Cannabinoid-based Medications to Treat COPD and Asthma

Fri, 23 Jun 2017 09:14:44 EDT

IRVINE, CA--(Marketwired - Jun 23, 2017) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it has invested in the research and development of new cannabinoid-based medications to treat Chronic Obstructive Pulmonary Disease (COPD) and Asthma. According to the Centers for Disease Control and Prevention, in the U.S. alone over 15 million people have been diagnosed with COPD, and over 25 million with Asthma.




Integrating Equipment Design, Logistics Processes and Real-Time Informatics: The Arrival of QbD in Pharmaceutical Logistics, New Webinar Hosted by Xtalks

Fri, 23 Jun 2017 07:30:00 EDT

Industry expert Mark W. Sawicki, Ph.D., chief commercial officer at Cryoport to discuss the Quality by Design process as it relates to logistics and evaluate its benefits during a live broadcast on Tuesday, July 11, 2017




Alpha Pro Tech, Ltd. Announces Additional $2 Million Expansion to Share Repurchase Program

Thu, 22 Jun 2017 16:15:00 EDT

NOGALES, AZ--(Marketwired - Jun 22, 2017) - Alpha Pro Tech, Ltd. (NYSE MKT: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced that its Board of Directors has authorized a $2.0 million expansion of the Company's existing share repurchase program.




Premier Diversified Holdings Inc. Completes Share Purchase

Thu, 22 Jun 2017 14:28:09 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 22, 2017) -




ECPO-Subsidiary Immunotech Laboratories Enters Final Step of Full Commercialization by the BDA post Phase 3 Approval of ITV-1 for HIV/AIDS; Also Announces Issuance of Distribution Agreement for the Ukraine

Thu, 22 Jun 2017 13:24:33 EDT

MONROVIA, CA--(Marketwired - Jun 22, 2017) - Eco Petroleum Solutions, Inc. ((OTC PINK: ECPO) or the "Company") announces that IMMB BG a subsidiary of Immunotech Laboratories, Inc., the Company's subsidiary, has issued an exclusive Distribution Agreement (the "Agreement") for the territory of the Ukraine to LLC Project Development and Implementation Centre Omega ("Omega"). The term of the agreement is for an initial ten-year period with an option to renew the agreement for an additional ten years. The Agreement establishes a price of EUR 3,300 (Euros) per one 8-week cycle of injections or 16 vials. The treatment protocol requires two 8-week cycles of injections administered twice a week with a one-week break between cycles. The ITV-1 treatment will be administered with a combination of different variations of Protease Inhibitors used in the treatment of HIV/AIDS.




Vancouver Medical Spa Joins the World of Facebook

Thu, 22 Jun 2017 13:22:21 EDT

Dr. Kamani plans to share knowledge of medical aesthetic procedures on beloved online platform




Vancouver Fire Protection Agency Now Helps Businesses With Emergency Light Testing

Thu, 22 Jun 2017 13:00:00 EDT

Vancouver fire protection company now conducts ASTTBC Certified Emergency Light Testing




Relevium Provides Corporate Update and Final Closing of the Equity Financing

Thu, 22 Jun 2017 10:12:16 EDT

MONTREAL, QUEBEC--(Marketwired - June 22, 2017) - Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the "Company" or "Relevium") a consolidator of e-commerce assets in Health and Wellness is pleased to provide a corporate update on its recent acquisition of BioGanix and the closing of the final tranche o of the equity financing.




UPDATE - Cannabis Science Releases the Chronic Pain CBIS Transdermal Patches to Meet the Overwhelming Demand from Self-Medicating Patients Worldwide as it Continues to Expands its California Dispensary Network

Thu, 22 Jun 2017 08:43:43 EDT

IRVINE, CA--(Marketwired - Jun 22, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its new product-development plans are well underway with the release of the first batch of the CBIS Transdermal Patch in response to an overwhelming response from hundreds chronic pain self-medicating patients worldwide with various chronic pain conditions including Neuropathy, Fibromyalgia, Diabetic Nerve Pain, Back Strains, and others.




Cannabis Science Releases the Chronic Pain CBIS Transdermal Patches to Meet the Overwhelming Demand from Self-Medicating Patients Worldwide as it Continues to Expands its California Dispensary Network

Thu, 22 Jun 2017 08:11:45 EDT

IRVINE, CA--(Marketwired - Jun 22, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its new product-development plans are well underway with the release of the first batch of the CBIS Transdermal Patch in response to an overwhelming response from hundreds chronic pain self-medicating patients worldwide with various chronic pain conditions including Neuropathy, Fibromyalgia, Diabetic Nerve Pain, Back Strains, and others.




Increasing Patient Enrollment and Patient Data Exchange: Digital Transformation in the Clinical Trial Process, New Webinar Hosted by Xtalks

Thu, 22 Jun 2017 07:30:00 EDT

Join this informative session as the speakers discuss ways to stimulate greater and faster recruitment as well as improve patient and research data harmonization and exchange, through a digital transformation




The Importance of Dose Prediction for Early Drug Development, New Webinar Hosted by Xtalks

Thu, 22 Jun 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - June 22, 2017) - During a live broadcast on Thursday, July 6, 2017, Dr. Robert Harris, Chief Technical Officer at Juniper Pharma Services and Dr. Graham Trevitt, Director (DMPK Consultancy, Modelling and Simulation) at XenoGesis will provide insight into how their joint consultative approach can help drug developers better understand the absorption and clearance characteristics of a drug substance and how these properties can influence dose prediction and selection of an appropriate formulation strategy.




Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS)

Thu, 22 Jun 2017 05:30:00 EDT

Report on Impact of NB1111 on Tissues that Regulate Intraocular Pressure (IOP) in an Animal Normotensive Ocular Model




Premier Diversified Holdings Inc. Announces Share Purchase

Wed, 21 Jun 2017 15:05:50 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 21, 2017) -




Nutra Pharma Announcing Launch of Luxury Feet

Wed, 21 Jun 2017 08:30:00 EDT

Nutra Pharma is announcing the launch of Luxury Feet; an over-the-counter pain reliever for women who experience pain or discomfort due to high heels and stilettos




Rennova Health Stockholders Approve Proposal at Special Meeting

Wed, 21 Jun 2017 08:30:00 EDT

WEST PALM BEACH, FL--(Marketwired - June 21, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces that its stockholders approved Proposal 1 at a Special Meeting of Stockholders held on June 16, 2017.




Vitality Biopharma Advisor to Present Pediatric IBD Case Study at ICRS2017 in Montreal

Wed, 21 Jun 2017 08:30:00 EDT

Dr. Natasha Ryz, a Vitality research advisor, will present a case study report on cannabinoid treatment for pediatric Crohn's disease




Amfil Technologies Inc. Announces Shareholder Dividend From Subsidiary Spin-Off

Wed, 21 Jun 2017 08:00:00 EDT

TORONTO, ON--(Marketwired - Jun 21, 2017) - Amfil Technologies Inc. (OTC PINK: AMFE) is pleased to announce that it has decided to spin-off the Interloc-Kings Inc. subsidiary into a new public entity, leaving Snakes & Lattes Inc. and GROzone as subsidiaries of Amfil Technologies Inc. (AMFE). In conjunction with the spin-off, shareholders will be awarded with a one-time share dividend in the newly formed entity based upon their holdings of Amfil Technologies Inc.




Moleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer

Wed, 21 Jun 2017 07:30:00 EDT

Metabolic Inhibitor Shows Greater Ability to Kill Pancreatic Cancer Cell Lines




Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials

Wed, 21 Jun 2017 06:02:00 EDT

BEVERLY HILLS, CA--(Marketwired - Jun 21, 2017) - Rich Pharmaceuticals, Inc. (OTC PINK: RCHA) ("Rich" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology announced today its principal doctor, Dr. Tontanai Numbenjapon, will commence clinical trials in Phramongkutklao Hospital in Thailand.




Premier Diversified Holdings Inc. Closes $270K Private Placement

Tue, 20 Jun 2017 16:30:41 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 20, 2017) -




Bioz Launches Partner Program for Life Science Tool Vendors

Tue, 20 Jun 2017 09:00:00 EDT

Partner Program Members Granted Unparalleled Access to Worldwide Biopharma and University Life Science Researchers During Experimentation Planning Process




MCIG to Manage and Staff Indoor Grow Facility in Las Vegas Through its Subsidiary, Grow Contractors

Tue, 20 Jun 2017 07:30:00 EDT

HENDERSON, NV--(Marketwired - Jun 20, 2017) - mCig, Inc., (OTCQB: MCIG), a leading distributor of innovative products, technologies, and services for the global medical cannabis industry is pleased to announce that Grow Contractors (GC) has signed a management contract to staff and manage a 15,000 square foot indoor cultivation facility in Las Vegas, Nevada for R.H. Medical.




Zecotek Receives Notice of Allowance in China for New Advanced Formulation of its Worldwide Patented LFS Scintillation Crystal

Tue, 20 Jun 2017 03:15:00 EDT

SINGAPORE--(Marketwired - June 20, 2017) - Zecotek Photonics Inc. (TSX VENTURE: ZMS) (FRANKFURT: W1I) (OTC PINK: ZMSPF), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, is pleased to announce that its wholly owned division, Zecotek Imaging Systems Pte. Ltd., has received a notice of allowance in China for its advanced formulation of its patented LFS scintillation crystals. This is the second patent in a series of worldwide, pending patents, for multi-doped lutetium oxide based scintillators having improved photonic properties, known as, "LFS-M".




Premier Diversified Holdings Inc. Announces Private Placement

Mon, 19 Jun 2017 17:08:06 EDT

BURNABY, BRITISH COLUMBIA--(Marketwired - June 19, 2017) -




UPDATE - Eco-Petroleum Solutions, Inc. Releases Letter from CEO and Chairman

Mon, 19 Jun 2017 12:51:54 EDT

ECPO Chairman and CEO Addresses Shareholders Informing Them of New Business Model




GeoVax Awarded NIH Grant for Zika Vaccine

Mon, 19 Jun 2017 12:00:00 EDT

Supports Advanced Preclinical Testing in Preparation for Human Clinical Trials